3 Medical Advancements You May Be Missing Out On
Motley Fool healthcare analysts highlight medical innovations that could prove to be profit friendly.
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool contributors offer up three potential acquisition targets for Pfizer.
3 Drugs That Could Become Blockbusters in 2015
Pharmacyclics, Celgene Corp., Bristol-Myers Squibb, and Pfizer could see sales of new drugs eclipse $1 billion this year.
3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool experts highlight three blockbuster-selling therapies that could fall by the wayside in the next five years.
Can You Guess the Stock Putting Gilead Sciences to Shame? (Hint: It's Not AbbVie)
Pharmacyclics and Johnson & Johnson's CLL drug Imbruvica is outselling Gilead Sciences Zydelig.
Merck Posts Disappointing Numbers As Experimental Hepatitis C Treatment Loses Breakthrough Designati
Merck Posts Disappointing Numbers As Experimental Hepatitis C Treatment Loses Breakthrough Designation